SAN MATEO, Calif. — Curve Biosciences, the Whole-Body Intelligence company, announced it has raised $40 million in funding to advance the clinical validation and commercialization of its Whole-Body Intelligence platform, which aims to transform how chronic diseases are monitored and managed. The funding round was led by Luma Group, with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and other investors.
Curve Biosciences has developed the first molecular blueprint of the human body through its Whole-Body Atlas — the world’s largest collection of manually curated tissue samples classified by organ and disease state. This data serves as the foundation for the company’s Whole-Body Blood Tests, designed to anticipate chronic disease, guide treatment decisions, and create alignment among patients, insurers, pharmaceutical companies, and physicians.
“Chronic diseases are on the rise, and healthcare costs are skyrocketing as a result. We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s,” said Ritish Patnaik, Ph.D., co-founder and chief executive officer of Curve Biosciences. “To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests. We’ve paired this platform with a seasoned executive team to realize our vision for proactive, personalized chronic care that minimizes suffering.”
Curve’s leadership team includes several veterans of precision diagnostics and biotechnology. Patnaik previously led business development at Genentech and brings expertise in AI, data engineering, and precision testing. Nathan Hunkapiller, Ph.D., serves as chief scientific officer after leading research and development at Natera and GRAIL, where he helped develop advanced blood tests for oncology and prenatal screening. Alice Chen, Ph.D., chief operating officer, formerly led product and program management at GRAIL, overseeing strategy for a multi-cancer early detection test. Chuba Oyolu, Ph.D., chief technology officer, was a founding scientist and senior site director at Counsyl, where he directed automation and scaling of blood testing technologies. The company’s chief innovation officer and scientific founder, Professor Shan Wang, Ph.D., is the Leland T. Edwards Professor in the School of Engineering at Stanford University and an inventor with more than 70 issued or pending patents.
Curve’s Whole-Body Intelligence platform represents a major step toward integrating molecular data with artificial intelligence to create actionable clinical insights. The company plans to announce additional details about its chronic disease monitoring pipeline in the coming months.
“We believe Curve’s Whole-Body Intelligence platform represents the next frontier in clinical testing, with the potential to fundamentally reshape how we monitor and manage chronic disease,” said Themasap Khan, Ph.D., co-founder and partner at Luma Group. “By anchoring in human tissue data, Curve is building a clinically actionable platform with clear reimbursement potential and broad market applicability.” (Source: IANS)
